



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

**DRAFT INTERIM GUIDELINES ON THE PROCESS AND METHODS FOR THE
SELECTION OF MEDICAL DEVICES FOR INCLUSION IN THE PHILIPPINE ESSENTIAL
MEDICAL DEVICE LIST (PEMDL) FOR COMMENTS UNTIL 21 SEPTEMBER 2022**

Pursuant to Republic Act 11223, otherwise known as the “Universal Health Care Act,” all health technologies that will be funded by the Department of Health and the Philippine Health Insurance Corporation shall undergo health technology assessment (HTA). This aims to establish the rational utilization of various health technologies that will be funded by the government.

To assist and guide all public health facilities to efficiently source quality and affordable medical devices and supplies in the public sector through the **Medical Devices and Supplies Price Reference Index (MDSPRI)**, the **Philippine Essential Medical Devices List (PEMDL)** shall be developed by the Department of Health through the Pharmaceutical Division - Medical Device Unit (PD-MDU) and the Health Technology Assessment Division (HTAD) in accordance with Administrative Order 2021-0038 or the “Framework of the Philippine Essential Medical Devices List and Price Reference Index”.

An Expert Advisory Committee (EAC) supported by staff from the PD-MDU was created under the Pool of Experts of the Health Technology Assessment Council (HTAC) which is supported by staff from the HTAD based on Department Personnel Order No. 2021-2780-A with the subject *Amendment to the Department Personnel Order No. 2021-2780 entitled “Creation of the pool of clinical experts for consultation on the evaluation of assessment topics” to include Expert Advisory Committee as additional experts* to assist in the assessment of essential medical devices and supplies to be included in the PEMDL.

The EAC and HTAC jointly developed a flowchart for the screening of medical devices proposed to be included in the initial PEMDL. The draft interim guidelines on this are hereby presented to all stakeholders, **for review and comments** until 21 September 2022. Please see the editable copy of the guidelines attached to this advisory.

Should you have comments and/or additional inputs with the draft guidelines, you may coordinate with HTAD through email at hta@doh.gov.ph or at telephone numbers (02) 875-7734 local 253 or 8937-5314. Thank you very much and best regards.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Director IV

Health Technology Assessment Division/Pharmaceutical Division

Health Regulation Team